Inventor
GLASS CHARLES A
US19 patents
⚠️ This page may combine multiple inventors who share the name “GLASS CHARLES A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BIOMARIN PHARM INC
10 patentsUS8809009B2Aug 19, 2014
Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
BIOMARIN PHARM INC14 citations92
US9222120B2Dec 29, 2015
Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition
BIOMARIN PHARM INC13 citations89
US9915649B2Mar 13, 2018
Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVA
BIOMARIN PHARM INC4 citations83
US9677116B2Jun 13, 2017
Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition
BIOMARIN PHARM INC4 citations83
US9340822B2May 17, 2016
Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
BIOMARIN PHARM INC12 citations83
US10260084B2Apr 16, 2019
Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition
BIOMARIN PHARM INC2 citations72
US9796999B2Oct 24, 2017
Detection of oligosaccharides
BIOMARIN PHARM INC1 citations62
US10793894B2Oct 6, 2020
Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition
BIOMARIN PHARM INC0 citations51
US10683530B2Jun 16, 2020
Detection of oligosaccharides
BIOMARIN PHARM INC0 citations51
US10677786B2Jun 9, 2020
Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
BIOMARIN PHARM INC0 citations51
CRAWFORD BRETT E
5 patentsUS8232073B2Jul 31, 2012
Quantification of non-reducing end glycan residual compounds
CRAWFORD BRETT E35 citations94
US8771974B2Jul 8, 2014
Methods of determining the presence and/or amount of a biomarker to determine the presence, identity, and/or severity of a lysosomal storage or neurological disorder
CRAWFORD BRETT E16 citations91
US8183003B2May 22, 2012
Polymer end group detection
CRAWFORD BRETT E22 citations91
US9029530B2May 12, 2015
Detection of oligosaccharides
CRAWFORD BRETT E4 citations83
US8592140B2Nov 26, 2013
Detection of oligosaccharides
CRAWFORD BRETT E12 citations83